Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura, is an acquired autoimmune disorder characterized by an isolated decrease in the number of circulating platelets (thrombocytopenia) below 100,000/microL in the absence of an identifiable cause or other hematologic abnormalities. The condition is driven by the production of autoantibodies, typically of the IgG class, which target platelet surface glycoproteins such as GPIIb/IIIa or GPIb/IX. These antibody-coated platelets are subsequently recognized by Fc receptors on splenic macrophages and removed from circulation. Additionally, the immune system may suppress the production of new platelets by affecting megakaryocytes in the bone marrow. ITP is classified into 'primary' when it occurs in isolation, and 'secondary' when it is associated with other conditions such as systemic lupus erythematosus (SLE), chronic lymphocytic leukemia (CLL), or infections like HIV, Hepatitis C, or Helicobacter pylori. Clinical presentation varies from asymptomatic laboratory findings to life-threatening hemorrhage.
Distinguish between primary and secondary ITP clearly in the documentation.
Example: Patient diagnosed with primary immune thrombocytopenic purpura (D69.3) after secondary causes including SLE, HIV, and Hepatitis C were ruled out via negative serology. The condition is currently chronic and refractory to first-line steroids. Risk adjustment is impacted by the chronic status and the need for second-line thrombopoietin receptor agonists.
Billing Focus: Documentation must specify the absence of underlying causative conditions to validate the use of the primary ITP code D69.3.
Document the specific phase of the disease: newly diagnosed, persistent, or chronic.
Example: Chronic immune thrombocytopenic purpura (D69.3) since diagnosis 14 months ago. Current platelet count is 22,000/mcL. Patient presents with mucosal bleeding (R04.0) and extensive lower extremity petechiae. Management involves transitioning to Romiplostim to maintain a target count above 50,000/mcL.
Billing Focus: Duration of the condition (e.g., over 12 months for chronic) supports the clinical severity profile and medical decision making (MDM) complexity.
Detail all active bleeding manifestations to support the severity of the encounter.
Example: Patient with known immune thrombocytopenic purpura (D69.3) presents with acute epistaxis and hematuria (R31.9). Physical exam reveals wet purpura on buccal mucosa. This represents an acute exacerbation requiring inpatient admission and high-dose IVIG therapy.
Billing Focus: Linking symptoms like hematuria or epistaxis to the underlying ITP code provides a more complete clinical picture for level 4 or 5 E/M coding.
Record the failure of previous therapies to justify the use of advanced biologics or surgical interventions.
Example: Refractory immune thrombocytopenic purpura (D69.3). Patient has failed prednisone (1mg/kg) and Rituximab. Considering splenectomy (CPT 38100) due to persistent platelets below 10,000/mcL and high risk for intracranial hemorrhage.
Billing Focus: Documenting treatment failure is essential for prior authorization of high-cost medications and justifying surgical procedures.
Explicitly exclude Evans Syndrome if only ITP is present to ensure coding specificity.
Example: Immune thrombocytopenic purpura (D69.3) confirmed. Concurrent autoimmune hemolytic anemia was excluded by a negative direct antiglobulin test (DAT), therefore Evans Syndrome (D59.13) is not present at this time.
Billing Focus: Differentiating D69.3 from D59.13 prevents over-coding and ensures the primary hematologic diagnosis is accurate.
Standard for managing chronic ITP where therapy is being adjusted or monitoring for bleeding manifestations is required.
Used when the patient has severe, refractory ITP with active bleeding or is considering high-risk interventions like splenectomy.
Essential for ruling out other causes of thrombocytopenia such as MDS or leukemia in atypical ITP presentations.
The primary monitoring tool for tracking platelet levels in ITP patients.
Used as rescue therapy in acute ITP or pre-operatively to quickly elevate platelets.
Used for the administration of second-line monoclonal antibody treatments for ITP.
A traditional second-line or third-line treatment for chronic, refractory ITP.
Critical to rule out pseudothrombocytopenia (clumping) and evaluate for schistocytes or blasts.
Used for initial hematology consultation for a patient with new-onset thrombocytopenia.
Appropriate for stable ITP patients in remission or on maintenance therapy with minimal changes.